These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 30658149)
1. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration. Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149 [TBL] [Abstract][Full Text] [Related]
2. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. Zharikov AD; Cannon JR; Tapias V; Bai Q; Horowitz MP; Shah V; El Ayadi A; Hastings TG; Greenamyre JT; Burton EA J Clin Invest; 2015 Jul; 125(7):2721-35. PubMed ID: 26075822 [TBL] [Abstract][Full Text] [Related]
3. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Khodr CE; Becerra A; Han Y; Bohn MC Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035 [TBL] [Abstract][Full Text] [Related]
4. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638 [TBL] [Abstract][Full Text] [Related]
5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577 [TBL] [Abstract][Full Text] [Related]
6. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration. Van Rompuy AS; Oliveras-Salvá M; Van der Perren A; Corti O; Van den Haute C; Baekelandt V Mol Neurodegener; 2015 Jun; 10():23. PubMed ID: 26099628 [TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127 [TBL] [Abstract][Full Text] [Related]
10. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo. Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984 [TBL] [Abstract][Full Text] [Related]
11. Cre-dependent AAV vectors for highly targeted expression of disease-related proteins and neurodegeneration in the substantia nigra. Grames MS; Dayton RD; Jackson KL; Richard AD; Lu X; Klein RL FASEB J; 2018 Aug; 32(8):4420-4427. PubMed ID: 29513569 [TBL] [Abstract][Full Text] [Related]
12. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease. Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446 [TBL] [Abstract][Full Text] [Related]
13. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease. Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678 [TBL] [Abstract][Full Text] [Related]
14. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra. Khodr CE; Pedapati J; Han Y; Bohn MC Dev Neurobiol; 2012 Jun; 72(6):906-17. PubMed ID: 22021082 [TBL] [Abstract][Full Text] [Related]
15. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease. Coune PG; Bensadoun JC; Aebischer P; Schneider BL J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344 [TBL] [Abstract][Full Text] [Related]
17. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy? Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708 [TBL] [Abstract][Full Text] [Related]
18. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Khodr CE; Sapru MK; Pedapati J; Han Y; West NC; Kells AP; Bankiewicz KS; Bohn MC Brain Res; 2011 Jun; 1395():94-107. PubMed ID: 21565333 [TBL] [Abstract][Full Text] [Related]
19. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra. Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851 [TBL] [Abstract][Full Text] [Related]
20. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]